ClinicalTrials.gg
CompletedNCT07089784Updated May 22, 2026

Multiple Dose Study of MK-2828 in Participants With Type 2 Diabetes (MK-2828-003)

A Phase 1 interventional study of MK-2828 and Placebo in Diabetes Mellitus, Type 2, sponsored by Merck Sharp & Dohme LLC. Completed at 11 sites in United States. Open to participants aged 24 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-05-22.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
46
Allocation
Randomized
Ages
24 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc — none open to participants now, none under way, none of them phase 3. Diabetes Mellitus, Type 2 · Merck & Co., Inc.

Enrollment
127th of 170
46 · median 192
Started
2025
with 1 other
Phase 1
55 of 181
none open now
Registered
180th of 181
by date

Among the 181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc, this one is the 127th largest by enrollment of the 170 interventional ones that give a count, is one of 2 that started in 2025, is one of 55 in phase 1, and was the 180th registered.

Diabetes Mellitus, Type 2

10,402 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

None of the 181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 24 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc as a file.
02

Study summary

The purpose of this study is to learn about the safety and if people tolerate a study medicine called MK-2828. The study will also measure what happens to MK-2828 in the body of a person with type 2 diabetes (T2D) over time (pharmacokinetic or PK study), and how it affects the amount of high-sensitivity C-reactive protein (hsCRP) in a person's blood.

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
24 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The main inclusion criteria include but are not limited to the following:

  • With the exception of type 2 diabetes mellitus (T2DM), is in generally good health
  • Has a history of T2DM for ≥1 year at the time of screening based on self-reporting
  • Has a baseline level of ≤10% at the time of screening
  • Has a stable weight (based on self-reporting) defined as ≤5 kg gain or loss of body weight for at least 3 months before Visit 1/Screening
  • T2DM treated with lifestyle modification alone or with stable doses (no significant change for ≥3 months from Visit 1/Screening, based on self-reporting) of ≤ 3 oral anti-diabetic medications and anticipated not to require dose adjustments during the study duration
  • (BMI) between 25 and 40 kg/m2, inclusive

Exclusion criteria

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

  • Has known systemic to the MK-2828 drug substance or other nucleotide-binding, leucine-rich, protein 3 inhibitor (NLRP3i) based therapy, its inactive ingredients, or the placebo
  • Has a history of congestive heart failure ( [NYHA] Class 3 or 4)
  • Has a history of myocardial infarction, uncontrolled arrhythmias, cardiac revascularization, unstable peripheral arterial disease and/or stroke within 6 months of screening
  • History of significant multiple and/or severe allergies (e.g., food, drug, latex allergy), or has had an anaphylactic reaction or significant intolerability (i.e., systemic allergic reaction) to prescription or nonprescription drugs or food
  • Has type 1 diabetes mellitus or secondary types of diabetes
  • Has experienced complications of diabetes such as ketoacidosis, unstable diabetic retinopathy, or maculopathy
  • Has previous or planned (during the trial period) obesity treatment with surgery or a weight loss device
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
46 participants (actual)

Study arms

  • Experimental
    MK-2828

    Participants receive daily MK-2828 for 28 days.

    Drug: MK-2828

  • Placebo comparator
    Placebo

    Participants receive daily placebo for 28 days.

    Drug: Placebo

Interventions

  • DrugMK-2828

    Oral capsule of MK-2828 taken once per day for 28 days.

  • DrugPlacebo

    Placebo to match MK-2828 oral capsule, taken once per day for 28 days.

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Experience an Adverse Event (AE)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: Up to approximately 42 days

  2. Number of Participants Who Discontinue Study Treatment Due to an AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: Up to approximately 28 days

Secondary outcomes

  1. Plasma Concentration of MK-2828 at 24 Hours Postdose (C24) After Day 1 Dose

    Blood samples will be collected to determine the C24 of MK-2828 in plasma after the Day 1 dose.

    Time frame: 24 hours post-Day 1 dose

  2. Plasma Concentration of MK-2828 at 24 Hours Postdose (C24) After Day 27 Dose

    Blood samples will be collected to determine the C24 of MK-2828 in plasma after the Day 27 dose.

    Time frame: Predose on Day 28

  3. Change from Baseline in Placebo Corrected High-Sensitivity C-Reactive Protein (hsCRP) Serum Concentration

    Blood samples will be collected to determine the change from baseline in placebo corrected hsCRP.

    Time frame: Baseline and Predose Day 28

07

Study locations

11 sites
  • ProSciento Inc. ( Site 0004)
    Chula Vista, California 91911, United States
  • California Clinical Trials Medical Group managed by PAREXEL ( Site 0008)
    Glendale, California 91206, United States
  • Velocity Clinical Research, Hallandale Beach ( Site 0010)
    Hallandale, Florida 33009, United States
  • Jacksonville Center for Clinical Research ( Site 0002)
    Jacksonville, Florida 32216, United States
  • Advanced Pharma CR, LLC ( Site 0001)
    Miami, Florida 33147, United States
  • QPS Miami Research Associates ( Site 0005)
    South Miami, Florida 33143, United States
  • AMR Lexington ( Site 0012)
    Lexington, Kentucky 40509, United States
  • Alliance for Multispecialty Research, LLC ( Site 0013)
    Kansas City, Missouri 64114, United States
  • Bio-Kinetic Clinical Applications, LLC dba QPS-MO ( Site 0009)
    Springfield, Missouri 65802, United States
  • AMR Clinical ( Site 0003)
    Knoxville, Tennessee 37920, United States
  • ICON Early Phase Services ( Site 0006)
    San Antonio, Texas 78209, United States
08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2025 to primary completion in May 2026, 7 months.

Of 454 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's 7 months is above that.

Counting every sponsor, half of 516 studies reached it within 6 months; a quarter within 2 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 25, 2025
First posted
Jul 28, 2025
StartActual
Sep 22, 2025
Primary completionActual
May 4, 2026
CompletionActual
May 4, 2026
Last update
May 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07089784
Responsible party
Sponsor
First posted
Jul 28, 2025
Start date
Sep 22, 2025
Primary completion
May 4, 2026
Completion
May 4, 2026
Last update
May 22, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion